generic neurology drugs

 

Published July 2017  ·  Report No. NRL449K · Price US $1,850

 


In terms of the number of unique products, drugs indicated for neurology conditions represent the largest practice sector market segment. Froma competitive standpoint, while several APIs appear to be saturated, there do exist a significant number of drugs and drug dosages that are currently underserved and may represent an unmet need. These instances represent potential opportunities for generic drug participants. This publication is designed to identify and highlight APIs and indications that allow decision makers to refine and optimize their generic drug strategies.

 

 

Report Brochure (Download PDF)

 

Report Order Form (Download PDF)

 


Generic Neurology Drugs – Content Highlights

  • Provides analysis of generic drugs indicated for the treatment of more than two dozen neurological conditions and indications
  • Presents the competitive picture for generic neurology drugs.
  • Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
  • Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
  • Assesses the market presence and product position of the top generic neurology drug suppliers

Generic Neurology Drugs – Summary of Contents

Generic Markets Overview
Major Market Segments for Generic Drugs
FDA Approved Generic Drugs by Therapeutic Class
Therapeutic Classes for Generic Neurology Drugs
Generic Neurology Drugs
Neurology – Generic Drug Competitive Index

Generic Neurology Drugs
Product Maps and Competitive Index
Indication: Anti-Seizure
Acetazolamide
Lacosamide
Oxcarbazepine
Phenytoin
Primidone
Indication: Antiemetic
Aprepitant
Dronabinol
Granisetron & Granisetron Hydrochloride
Trimethobenzamide
Indication: Antisedation
Flumazenil
Indication: Antispasmodic
Baclofen
Cyclobenzaprine
Dantrolene
Indication: Anxiety & Anxiety Disorders
Buspirone
Mebrobamate
Alprazolam
Clorazepate
Lorazepam
Phemtermine & Phentermine+Topiramate
Indication: Attention Deficit Disorders
Amphetamines
Amoxetine
Dexmethylphenidate
Dextroamphetamine
Methylphenidate
Indication: CINV
Ondansetron
Indication: Dementia
Donepezil
Galantamine
Memantine
Rivastigmine
Indication: Depression
Amitriptyline
Citalopram
Imipramine
Nortriptyline
Trazodone
Indication: Epilepsy
Carbamazepine
Divalproex
Ethosuxamide
Felbamate
Gabapentin
Lamotrigine
Levetiracetam
Topiramate
Valproic Acid
Eszopiclone
Temazepam
Zaleplon
Zolpidem Tartrate
Indication: Major Depressive Disorder
Bupropion
Desvenlafaxine
Duloxetine
Escitalopram
Fluoxetine
Mirtazapine
Paroxetine
Sertraline
Venlafaxine
Indication: Migraine
Naratriptan
Rizatriptan
Sumatriptan
Zolmitriptan
Indication: Myasthenia Gravis
Pyridostigmine
Indication: Neuroleptic
Fluphenazine
Haloperidol
Indication: Neuromuscular
Benztropine Mesylate
Dopamine
Indication: Nonpsychotic Anxiety
Prochlorperazine
Indication: Obsessive Compulsive Disorder
Fluvoxamine
Indication: Panic Disorders
Clonazepam
Indication: Parkinson’s Disease
Benztropine
Carbidopa & Carbidopa/Levodopa
Carbidopa/Entacapone/Levodopa
Pramipexole
Ropinirole
Selegiline
Indication: Psychoneurosis
Hydroxyzine
Doxepin

Key Generic Drug Opportunity Factors
Saturation Index
API Opportunity Index
P(iv) Neurology Drug Index
Orange Book Neurology Drug Patent Staircase Analysis

Generic Neurology Drugs – Company Activity Maps
Detailed Charts for the top 25 Neurology Sector Generic Participant